Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
bioMérieux
Baxter International
- License Information
-
More Information
Article History
Accepted: 21 May 2025
First Online: 3 June 2025
Declarations
:
: HG has received research grants (funding and in-kind) from bioMérieux, Baxter, and TES Pharma, and consulting fees from Trilinear bioventures. JAK discloses paid consulting from AstraZeneca, Bayer, bioMérieux, Chugai Pharma, Mitsubishi Tenabe, and Novartis, and employment/stock with Spectral Medical Inc. XC has no conflicts of interest.
: This study was approved by the University of Pittsburgh’s Institutional Review Board (IRB No. STUDY20040271) with exemption from obtaining informed consent and has, therefore, been performed in accordance with the ethical standards contained in the Declaration of Helsinki and its later amendments.
